Biotricity (OTCMKTS:BTCY – Get Free Report) and 10x Genomics (NASDAQ:TXG – Get Free Report) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, valuation, dividends, risk, analyst recommendations and earnings.
Analyst Recommendations
This is a summary of current ratings and recommmendations for Biotricity and 10x Genomics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Biotricity | 0 | 0 | 0 | 0 | 0.00 |
| 10x Genomics | 3 | 9 | 4 | 0 | 2.06 |
10x Genomics has a consensus target price of $17.68, suggesting a potential downside of 5.06%. Given 10x Genomics’ stronger consensus rating and higher possible upside, analysts clearly believe 10x Genomics is more favorable than Biotricity.
Volatility and Risk
Profitability
This table compares Biotricity and 10x Genomics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Biotricity | -25.99% | N/A | -67.82% |
| 10x Genomics | -6.77% | -6.99% | -5.44% |
Valuation and Earnings
This table compares Biotricity and 10x Genomics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Biotricity | $13.79 million | 0.51 | -$8.42 million | ($0.16) | -1.58 |
| 10x Genomics | $642.82 million | 3.67 | -$43.54 million | ($0.35) | -53.20 |
Biotricity has higher earnings, but lower revenue than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Biotricity, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
3.9% of Biotricity shares are owned by institutional investors. Comparatively, 84.7% of 10x Genomics shares are owned by institutional investors. 10.1% of Biotricity shares are owned by company insiders. Comparatively, 10.0% of 10x Genomics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Summary
10x Genomics beats Biotricity on 9 of the 14 factors compared between the two stocks.
About Biotricity
Biotricity, Inc., a medical technology company, provides biometric data monitoring solutions in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux mobile cardiac telemetry solution, an integrated ECG device; and ECG analysis software that analyzes and synthesizes patient ECG monitoring data, as well as software components. The company is based in Redwood City, California.
About 10x Genomics
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
Receive News & Ratings for Biotricity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biotricity and related companies with MarketBeat.com's FREE daily email newsletter.
